Objectives

- To evaluate clinician- and patient-reported outcomes (ClinRO; PRO) for tirbanibulin treatment satisfaction and effectiveness among patients administered tirbanibulin in routine clinical practice across the U.S.

Methods

- A single-arm, multicenter, prospective cohort study (PPOAK: NCT05260073) was conducted in adults with AKs on 25 cm² on the face or scalp and treated with once-daily tirbanibulin 1% ointment (5 consecutive days course) as part of usual care.
- Patients and clinicians completed surveys and clinical assessments at baseline, Week-8, and Week-24.

ClinRO and PRO comprised:

- **Treatment Satisfaction Questionnaire for Medication (TSQM-9):** with 3 domains (treatment effectiveness, convenience of use, and global satisfaction with treatment).
- **Expert Panel (EPQ):** assessing overall skin appearance, satisfaction with improvement in "skin texture" and "how skin looks", and likelihood to consider tirbanibulin again.

Clinicians assessed AK responses using Investigator’s Global Assessment (IGA) and patients’ skin photodamage severity scale. IGA success was defined as achieving IGA score of 0-1 (>75% AK lesions清除).

Data at Week-8 was already published. Here we present the results at Week-24.

Results

- A total of 278 patients completed study assessments at Week-24 (mean age: 66.3 years: 68.6% males; Fitzpatrick I/II/III).
- At Week-24, clinicians and patients reported similar, high levels of tirbanibulin treatment satisfaction for the 3 domains of TSQM-9 (Figure 1).
- At Week-24, clinicians and patients reported a high level of satisfaction with tirbanibulin treatment to improve "how skin looks" and "skin texture" (Figure 2), and high likelihood for considering tirbanibulin treatment in the future (Figure 3).
- At Week-24, 83.6% of clinicians and 78.5% of patients rated overall skin appearance after tirbanibulin treatment to be mostly somewhat/much improved.

Conclusion

- In real world, AK lesion clearance 75% (effectiveness) was stable over time (same in Week-8 [73.8% patients] and Week-24 [71.9% patients]).
- ClinROs and PROs demonstrated high satisfaction with once-daily tirbanibulin treatment for 5 consecutive days at Week-24, and both clinicians and patients reported a desire to consider tirbanibulin treatment in the future.

References


Acknowledgements

This study was funded by Almirall, Barcelona, Spain. Writing assistance provided by TFS HealthScience and funded by Almirall.